Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by chipmuki1234567on May 26, 2017 12:01am

123 Views

Post# 26286517

$2.7M raised Dec 2016 + $1M licensing = $1.16M Cash on hand?

Dec 17 Financials state $1.9M cash on hand. You got another $1M from regional financing and you have $1.16M to contribute from cash on hand towards Phase 2b testing for ATB 346... ummm John Wallace care to explain a bit here....

HOW MUCH MONEY IS CITAGENIX CONSUMING IN 3 MONTHS? ARE SALES DECLINING? WE KNOW THAT SALES WILL NOT REACH $10M ANNUAL AS WAS ORIGINALLY STATED DURING THE CITAGENIX PURCHASE..

Bullboard Posts

BlackBerry partners with Avathon to enhance critical event management with AI